References
- Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12(20 Pt 2): 6243s-9s. doi: 10.1158/1078-0432.CCR-06-0931
- Kumar N, Malhotra R, Zaw AS, Maharajan K, Naresh N, Kumar A, et al. Evolution in treatment strategy for metastatic spine disease: presently evolving modalities. Eur J Surg Oncol 2017; 43: 1784-801. doi: 10.1016/j. ejso.2017.05.006
- Kumar N, Zaw AS, Khine HE, Maharajan K, Wai KL, Tan B, et al. Blood loss and transfusion requirements in metastatic spinal tumor surgery: evaluation of influencing factors. Ann Surg Oncol 2016; 23: 2079-86. doi: 10.1245/s10434-016-5092-8
- Clausen C, Dahl B, Frevert SC, Hansen LV, Nielsen MB, Lonn L. Preoperative embolization in surgical treatment of spinal metastases: single-blind, randomized controlled clinical trial of efficacy in decreasing intraoperative blood loss. J Vasc Interv Radiol 2015; 26: 402-12.e1. doi: 10.1016/j. jvir.2014.11.014
- Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003; 300: 1155-9. doi: 10.1126/science.1082504
- Sathishkumar S, Boyanovsky B, Karakashian AA, Rozenova K, Giltiay NV, Kudrimoti M, et al. Elevated sphingomyelinase activity and ceramide concentration in serum of patients undergoing high dose spatially fractionated radiation treatment: implications for endothelial apoptosis. Cancer Biol Ther 2005; 4: 979-86. doi: 10.4161/cbt.4.9.1915
- Song CW, Kim MS, Cho LC, Dusenbery K, Sperduto PW. Radiobiological basis of SBRT and SRS. Int J Clin Oncol 2014; 19: 570-8. doi: 10.1007/s10147-014-0717-z
- Chu S, Karimi S, Peck KK, Yamada Y, Lis E, Lyo J, et al. Measurement of blood perfusion in spinal metastases with dynamic contrast-enhanced magnetic resonance imaging: evaluation of tumor response to radiation therapy. Spine 2013; 38: E1418-24 doi: 10.1097/BRS.0b013e3182a40838
- Kumar KA, Peck KK, Karimi S, Lis E, Holodny AI, Bilsky MH, et al. A pilot study evaluating the use of dynamic contrast-enhanced perfusion MRI to predict local recurrence after radiosurgery on spinal metastases. Technol Cancer Res Treat 2017; 16: 857-65. doi: 10.1177/1533034617705715
- Lis E, Saha A, Peck KK, Zatcky J, Zelefsky MJ, Yamada Y, et al. Dynamic contrast-enhanced magnetic resonance imaging of osseous spine metastasis before and 1 hour after high-dose image-guided radiation therapy. Neurosurg Focus 2017; 42: E9. doi: 10.3171/2016.9.FOCUS16378
- Lee JH, Yoo GS, Yoon YC, Park HC, Kim HS. Diffusion-weighted and dynamic contrast-enhanced magnetic resonance imaging after radiation therapy for bone metastases in patients with hepatocellular carcinoma. Sci Rep 2021; 11: 10459. doi: 10.1038/s41598-021-90065-1
- Yankeelov TE, Gore JC. Dynamic contrast enhanced magnetic resonance imaging in oncology: Theory, data acquisition, analysis, and examples. Curr Med Imaging Rev 2009; 3: 91-107. doi: 10.2174/157340507780619179
- Koh TS, Bisdas S, Koh DM, Thng CH. Fundamentals of tracer kinetics for dynamic contrast-enhanced MRI. J Magn Reson Imaging 2011; 34: 1262-76. doi: 10.1002/jmri.22795
- Cox BW, Spratt DE, Lovelock M, Bilsky MH, Lis E, Ryu S, et al. International Spine Radiosurgery Consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 2012; 83: e597-605. doi: 10.1016/j.ijrobp.2012.03.009
- Sahgal A, Weinberg V, Ma L, Chang E, Chao S, Muacevic A, et al. Probabilities of radiation myelopathy specific to stereotactic body radiation therapy to guide safe practice. Int J Radiat Oncol Biol Phys 2013; 85: 341-7 doi: 10.1016/j.ijrobp.2012.05.007
- Costelloe CM, Chuang HH, Madewell JE, Ueno NT. Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST. J Cancer 2010; 1: 80-92. doi: 10.7150/jca.1.80.
- Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999; 10: 223-32. doi: 10.1002/(sici)1522-2586(199909)10:3<223::aid-jmri2>3.0.co;2-s
- Khalifa F, Soliman A, El-Baz A, Abou El-Ghar M, El-Diasty T, Gimel’farb G, et al. Models and methods for analyzing DCE-MRI: a review. Med Phys 2014; 41: 124301 doi: 10.1118/1.4898202
- Dubois N, Rio E, Ripoche N, Ferchaud-Roucher V, Gaugler MH, Campion L, et al. Plasma ceramide, a real-time predictive marker of pulmonary and hepatic metastases response to stereotactic body radiation therapy combined with irinotecan. Radiother Oncol 2016; 119: 229-35. doi: 10.1016/j. radonc.2016.03.014